Name: Gedatolisib-[d4]
Brand: BOC Sciences
Rating: 5 (1 reviews)

General Information

Catalog: BLP-003850

Molecular Formula: C32H37D4N9O4

Molecular Weight: 619.75

Chemical Structure

Description	Gedatolisib-[d4], is the labelled analogue of Gedatolisib, which is a highly potent dual inhibitor of PI3Kα, PI3Kγ and mTOR with IC50 of 0.4 nM, 5.4 nM and 1.6 nM, respectively. Phase 2.
Synonyms	PKI587 D4; Gedatolisib-d4
IUPAC Name	1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[2,3,5,6-tetradeuterio-4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]urea
Related CAS	1197160-78-3 (unlabelled)
Canonical SMILES	CN(C)C1CCN(CC1)C(=O)C2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)C4=NC(=NC(=N4)N5CCOCC5)N6CCOCC6
InChI	InChI=1S/C32H41N9O4/c1-38(2)27-11-13-39(14-12-27)29(42)24-5-9-26(10-6-24)34-32(43)33-25-7-3-23(4-8-25)28-35-30(40-15-19-44-20-16-40)37-31(36-28)41-17-21-45-22-18-41/h3-10,27H,11-22H2,1-2H3,(H2,33,34,43)/i5D,6D,9D,10D
InChI Key	DWZAEMINVBZMHQ-GOOBIQQWSA-N
Purity	>98%

Gedatolisib-[d4] is a deuterated variant of the potent and selective dual inhibitor of PI3K/mTOR pathways used in various research and clinical contexts. Here are some key applications of Gedatolisib-[d4]:

Pharmacokinetic Studies: Gedatolisib-[d4] is utilized in pharmacokinetic research to understand drug metabolism and distribution. The deuterium labeling helps distinguish it from its non-deuterated counterpart, allowing for precise tracking within biological systems. This can improve the accuracy of pharmacokinetic models and aid in the development of dosing regimens.

Cancer Research: In oncology research, Gedatolisib-[d4] is employed to study the inhibition of PI3K/mTOR pathways, which are crucial in cancer cell survival and proliferation. By using this variant, researchers can assess the therapeutic potential and efficacy in preclinical cancer models. These studies are instrumental in the development of targeted cancer therapies.

Drug-Drug Interaction Studies: Gedatolisib-[d4] is used in drug interaction studies due to its deuterated nature, which can result in altered metabolic stability. Researchers can investigate how Gedatolisib-[d4] interacts with other drugs by examining its pharmacological effects when administered alongside other therapeutic agents. This provides insights into potential safety and efficacy concerns in combinational therapies.

Biomarker Development: Gedatolisib-[d4] can be applied in the identification and validation of biomarkers related to PI3K/mTOR pathway activity. By observing responses in cells and tissues treated with this compound, scientists can identify signaling molecules that correlate with pathway inhibition.